Highest-materiality recent filing
Simulations Plus Q3 revenue $21.9M (+7% YoY); merger with Altaris on track
Q3 revenue $21.9M (+7% YoY); software flat at $12.6M, services up 20% to $9.3M.
Simulations Plus to be acquired by Altaris affiliate for $18.50 per share in all-cash deal
Each common share will be converted into $18.50 in cash, representing a premium to the last close.
Simulations Plus to be acquired by Altaris for $375M, $18.50/share cash
All-cash acquisition at $18.50/share, 26% premium to 60-day VWAP.
Total revenue $24.3M (+8% YoY); software $14.6M (+9%), services $9.7M (+8%). Gross margin improved to 66% from 59%.
Simulations Plus Q1 revenue down 3% to $18.4M; adjusted EPS falls to $0.13
Revenue $18.4M (-3% YoY); software $8.9M (-17%), services $9.5M (+16%).
Simulations Plus Q4 revenue down 6% to $17.5M, posts net loss; reaffirms FY2026 guidance
Q4 total revenue $17.5M (-6% YoY); software $9.0M (-9%); services $8.4M (-3%).
Simulations Plus provides preliminary FY2025 revenue of $79.1M and FY2026 guidance of $79-82M
Preliminary FY2025 revenue $79.1M (+13% YoY); adjusted diluted EPS guidance $1.03-$1.10 for FY2026.
Simulations Plus dismisses Grant Thornton, reappoints RSJ as auditor citing 10-Q timeline concerns
Dismissed Grant Thornton LLP on July 9, 2025; re-hired Rose, Snyder & Jacobs LLC for FY2025.
Simulations Plus Q3 net loss $67.3M on $77.2M impairment; adjusted EPS $0.45 tops year-ago $0.27
Total revenue $20.4M (+10% YoY); software $12.6M (+6%), services $7.7M (+17%).
Simulations Plus pre-announces Q3 revenue $19-20M; lowers FY2025 guidance to $76-80M
Preliminary Q3 FY2025 revenue expected between $19M and $20M.
Simulations Plus Q3 FY2025 revenue prelim $19-20M; full-year guidance cut to $76-80M
Preliminary Q3 FY2025 revenue expected $19-20M, subject to final adjustment.
John DiBella appointed Chief Revenue Officer; Daniel Szot departs at end of fiscal Q3 for other opportunities.
Simulations Plus Q2 revenue $22.4M (+23% YoY); EPS $0.15 vs $0.20; adjusted EPS $0.31
Total revenue $22.4M, +23% YoY; software $13.5M (+16%), services $8.9M (+34%).
Simulations Plus Q1 FY25 revenue up 31% to $18.9M; software up 41%, adjusted EPS $0.17
Total revenue $18.9M (+31% YoY); software revenue $10.7M (+41%) driven by MonolixSuite (+43%) and QSP (+40%).
Simulations Plus FY2024 revenue $70M (+18% YoY); guides FY2025 $90-93M rev, adj. EPS $1.07-1.20
Q4 FY2024 revenue $18.7M (+19% YoY); diluted EPS $0.04, adjusted diluted EPS $0.06.
Simulations Plus Announces Leadership Changes and Business Unit Restructuring
Steven Chang promoted to President, Quantitative Systems Pharmacology, effective August 30, 2024.
Simulations Plus Q3 revenue $18.5M (+14% YoY), EPS $0.15; discontinues dividend
Total revenue $18.5M, up 14% YoY; net income $3.1M vs $4.0M; diluted EPS $0.15 vs $0.20.
All-cash purchase of Pro-ficiency for $100M; funded from existing cash and investments; no debt retained after deal.
Simulations Plus Q2 rev $18.3M (+16%); EPS $0.20 flat; FY guidance reaffirmed
Revenue $18.3M (+16% YoY); software $11.6M (+11%), services $6.7M (+27%).
Simulations Plus Q1 revenue $14.5M (+21% YoY), EPS $0.10; maintains FY guidance; appoints COO
Q1 revenue $14.5M (+21% YoY), diluted EPS $0.10 (vs $0.06), adjusted EBITDA $3.4M (23% of revenue).
Simulations Plus Q4 revenue up 33% to $15.6M; guides FY2024 revenue $66-69M
Q4 total revenue $15.6M (+33% YoY); software revenue $9.3M (+59%), services $6.3M (+8%).
Q3 revenue $16.2M (+9% YoY); diluted EPS $0.20 (flat); adjusted EBITDA $6.5M (40% margin).
Simulations Plus acquires Immunetrics for $15.5M+$8M earnout to expand QSP capabilities
Total consideration up to $23.5M: $15.5M cash at closing (incl. $1.8M holdback) plus up to $8M earnout based on 2023-2024 revenue.
Simulations Plus Q1 revenue down 4% to $12M; EPS falls to $0.06; announces $50M buyback
Q1 revenue $12.0M (-4% YoY); diluted EPS $0.06 vs $0.15; net income $1.2M.
Simulations Plus FY2022 revenue $53.9M (+16%), EPS $0.60; guides FY2023 rev $59.3M-$62.0M
Full-year revenue $53.9M (+16% YoY); diluted EPS $0.60 (+28% YoY).
Simulations Plus Q3 revenue $15.0M (+17%), EPS $0.20, declares $0.06 dividend
Total revenue $15.0M (+17% YoY); software $9.7M (+16%), services $5.3M (+19%).
Simulations Plus Q2 revenue up 13% to $14.8M; EPS up 40% to $0.21; declares $0.06 dividend
Total revenue $14.8M (+13% YoY); software revenue $9.8M (+25%), services $5.0M (-5%).
Erik Guffrey , currently Chief Technology Officer, Adaptive Learning & Insights and Medical Communications Products, assumes the new role of Co-Chief Product and Technology Officer.
Dr. Jonathan Chauvin , currently Business Unit Co-President, Clinical Pharmacology & Pharmacometric Solutions, assumes the new role of Co-Chief Product and Technology Officer.
Josh Fohey , currently Senior Vice President, Operations, assumes the new role of Chief Operating Officer.
On May 30, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Simulations Plus, Inc. (the “Company”) appointed John DiBella as Chief Revenue Officer of the Company, effective immediately.
Steven Chang , currently Business Unit President, Quantitative Systems Pharmacology Solutions, assumes the new role of Global Head of Strategic Alliances.
Jill Fiedler-Kelly , currently Business Unit Co-President, Clinical Pharmacology & Pharmacometric Solutions, assumes the new role of Interim President, Services Solutions.
Will Frederick , currently Chief Financial Officer and Chief Operating Officer, assumes the new role of Executive Vice President and Chief Financial Officer.
On the Effective Date, the Company and Daniel Szot, the Company’s Chief Revenue Officer, mutually agreed to Mr. Szot’s separation from the Company, to take effect at the end of the third fiscal quarter which allows for smooth transition as Mr. Szot seeks to pursue other opportunities.
Effective August 30, 2024, Dr. Brett Howell, Ph.D., has departed the Company.
on June 11, 2024, Michael Raymer, the chief executive officer of Pro-ficiency pre-Acquisition, was appointed as Business Unit President of the Company
Will Frederick, the Company’s Chief Financial Officer, was appointed to the additional role of Chief Operating Officer.
Steven Chang, the Chief Executive Officer of Immunetrics pre-Merger, was appointed as President of the Surviving Corporation
Max materiality 0.90 · Median 0.60 · Most common event earnings